White Paper: Engaging With Integrated Delivery Networks to Address the Social Determinants of Health
Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life.
In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.
Cell and gene therapy: the impact of skills gaps in a fast-growing sector
The growing skills gaps in cell and gene therapy have resulted in a bottleneck preventing potentially revolutionary treatments from reaching the patients who need them. Phil Massey and Daniel Foody of Project Farma, part of the Precision ADVANCE collective, weigh in on the effects of the talent gap, and discuss strategies for closing the gap.
Conference Video: World EPA Congress
Congratulations to PRECISIONadvisor’s Richard Macaulay on presenting “The Future of Innovative Reimbursement for Cell and Gene Therapies” at World EPA Congress 2021.
“Behind the Deal”: Blackstone’s investment in Precision Medicine Group
White Paper: Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing
Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.
This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).